{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T17:05:32Z","timestamp":1779555932249,"version":"3.53.1"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100025178","name":"OpenAI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100025178","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000147","name":"Canadian Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000147","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["CIHR PJT-186077"],"award-info":[{"award-number":["CIHR PJT-186077"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000521","name":"Canadian Cancer Society","doi-asserted-by":"publisher","award":["708370"],"award-info":[{"award-number":["708370"]}],"id":[{"id":"10.13039\/501100000521","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.exphem.2026.105406","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T16:01:55Z","timestamp":1773763315000},"page":"105406","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Current landscape of mRNA therapeutics for acute myeloid leukemia"],"prefix":"10.1016","volume":"158","author":[{"given":"Mira","family":"Hamed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8299-9692","authenticated-orcid":false,"given":"Olivia","family":"Kovecses","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3750-6027","authenticated-orcid":false,"given":"Maureen","family":"McKeague","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2026.105406_bib0001","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/ajh.27625","article-title":"Acute myeloid leukemia: 2025 update on diagnosis, risk-stratification, and management","volume":"100","author":"Shimony","year":"2025","journal-title":"Am J Hematol"},{"key":"10.1016\/j.exphem.2026.105406_bib0002","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2026.105406_bib0003","first-page":"46","article-title":"Acute myeloid leukemia management and research in 2025","volume":"75","author":"Kantarjian","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.exphem.2026.105406_bib0004","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1002\/gcc.22806","article-title":"Clonal evolution of acute myeloid leukemia from diagnosis to relapse","volume":"58","author":"Vosberg","year":"2019","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.exphem.2026.105406_bib0005","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1182\/blood-2016-10-696054","article-title":"Biology and relevance of human acute myeloid leukemia stem cells","volume":"129","author":"Thomas","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2026.105406_bib0006","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics\u2013developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.exphem.2026.105406_bib0007","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"Weissman D. mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.exphem.2026.105406_bib0008","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12929-024-01080-z","article-title":"Current landscape of mRNA technologies and delivery systems for new modality therapeutics","volume":"31","author":"Lu","year":"2024","journal-title":"J Biomed Sci"},{"key":"10.1016\/j.exphem.2026.105406_bib0009","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/s41587-022-01491-z","article-title":"Unlocking the promise of mRNA therapeutics","volume":"40","author":"Rohner","year":"2022","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.exphem.2026.105406_bib0010","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Na Rev Mater"},{"key":"10.1016\/j.exphem.2026.105406_bib0011","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/s41375-024-02191-0","article-title":"Nucleic acid therapeutics as differentiation agents for myeloid leukemias","volume":"38","author":"Kovecses","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2026.105406_bib0012","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","article-title":"Drug delivery systems for RNA therapeutics","volume":"23","author":"Paunovska","year":"2022","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.exphem.2026.105406_bib0013","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nnano.2014.84","article-title":"In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight","volume":"9","author":"Dahlman","year":"2014","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.exphem.2026.105406_bib0014","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1089\/nat.2018.0721","article-title":"Lipid nanoparticles enabling gene therapies: from concepts to clinical utility","volume":"28","author":"Kulkarni","year":"2018","journal-title":"Nucleic Acid Ther"},{"key":"10.1016\/j.exphem.2026.105406_bib0015","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.1021\/acs.molpharmaceut.5c00385","article-title":"Recent advances in mRNA-LNP delivery systems for extrahepatic organs: a review","volume":"22","author":"Bai","year":"2025","journal-title":"Molr Pharm"},{"key":"10.1016\/j.exphem.2026.105406_bib0016","doi-asserted-by":"crossref","first-page":"17095","DOI":"10.1021\/jacs.8b08976","article-title":"Nanoparticles that deliver RNA to bone marrow identified by in vivo directed evolution","volume":"140","author":"Sago","year":"2018","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.exphem.2026.105406_bib0017","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nature17624","article-title":"Distinct bone marrow blood vessels differentially regulate haematopoiesis","volume":"532","author":"Itkin","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2026.105406_bib0018","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nature12984","article-title":"The bone marrow niche for haematopoietic stem cells","volume":"505","author":"Morrison","year":"2014","journal-title":"Nature"},{"issue":"Suppl 1","key":"10.1016\/j.exphem.2026.105406_bib0019","doi-asserted-by":"crossref","first-page":"4923","DOI":"10.1182\/blood-2022-159085","article-title":"Direct delivery of mRNA-loaded lipid nanoparticles to the hematopoietic stem cell niche","volume":"140","author":"Banda","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2026.105406_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102423","article-title":"Restoring hematopoietic stem and progenitor cell function in Fancc (-\/-) mice by in situ delivery of RNA lipid nanoparticles","volume":"36","author":"Banda","year":"2025","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.exphem.2026.105406_bib0021","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1021\/acs.nanolett.3c00304","article-title":"In vivo RNA delivery to hematopoietic stem and progenitor cells via targeted lipid nanoparticles","volume":"23","author":"Shi","year":"2023","journal-title":"Nano Lett"},{"key":"10.1016\/j.exphem.2026.105406_bib0022","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1126\/science.ade6967","article-title":"In vivo hematopoietic stem cell modification by mRNA delivery","volume":"381","author":"Breda","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.exphem.2026.105406_bib0023","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41565-024-01847-3","article-title":"Nature-inspired platform nanotechnology for RNA delivery to myeloid cells and their bone marrow progenitors","volume":"20","author":"Hofstraat","year":"2025","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.exphem.2026.105406_bib0024","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/s41565-024-01680-8","article-title":"Bone-marrow-homing lipid nanoparticles for genome editing in diseased and malignant haematopoietic stem cells","volume":"19","author":"Lian","year":"2024","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.exphem.2026.105406_bib0025","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1038\/s41587-024-02470-2","article-title":"Lipid nanoparticle-mediated mRNA delivery to CD34+ cells in rhesus monkeys","volume":"43","author":"Kim","year":"2025","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.exphem.2026.105406_bib0026","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41551-025-01480-y","article-title":"In vivo genome editing of human haematopoietic stem cells for treatment of blood disorders using mRNA delivery","volume":"10","author":"Xu","year":"2025","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.exphem.2026.105406_bib0027","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.70447","article-title":"Revolution of AAV in drug discovery: from delivery system to clinical application","volume":"97","author":"Yin","year":"2025","journal-title":"J Med Virol"},{"key":"10.1016\/j.exphem.2026.105406_bib0028","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.omtn.2020.03.009","article-title":"Enhanced transduction of human hematopoietic stem cells by AAV6 vectors: implications in gene therapy and genome editing","volume":"20","author":"Yang","year":"2020","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.exphem.2026.105406_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101438","article-title":"Highly efficient in vivo hematopoietic stem cell transduction using an optimized self-complementary adeno-associated virus","volume":"33","author":"Charlesworth","year":"2025","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.exphem.2026.105406_bib0030","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1089\/hum.2020.049","article-title":"Adeno-associated virus and hematopoietic stem cells: the potential of adeno-associated virus hematopoietic stem cells in genetic medicines","volume":"31","author":"Chatterjee","year":"2020","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.exphem.2026.105406_bib0031","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.exphem.2026.105406_bib0032","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/S0140-6736(23)02444-3","article-title":"mRNA-based therapeutics: looking beyond COVID-19 vaccines","volume":"403","author":"Parhiz","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.exphem.2026.105406_bib0033","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1182\/blood.2024024008","article-title":"DiNardo CD. How I treat acute myeloid leukemia with differentiation therapy","volume":"145","author":"Issa","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2026.105406_bib0034","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41408-021-00584-3","article-title":"Differentiation therapy for myeloid malignancies: beyond cytotoxicity","volume":"11","author":"Stubbins","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.exphem.2026.105406_bib0035","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1158\/2643-3230.BCD-24-0171","article-title":"Venetoclax-based combination regimens in acute myeloid leukemia","volume":"6","author":"Goulart","year":"2025","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.exphem.2026.105406_bib0036","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2026.105406_bib0037","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.stem.2012.01.006","article-title":"Hematopoiesis: a human perspective","volume":"10","author":"Doulatov","year":"2012","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.exphem.2026.105406_bib0038","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJMoa1207285","article-title":"Cord-blood engraftment with ex vivo mesenchymal-cell coculture","volume":"367","author":"de Lima","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2026.105406_bib0039","article-title":"Transfer of mRNA encoding CEBPA in lipid nanoparticles to CEBPA mutated leukemia cell line KO52 and primary AML reduces cell growth and induces myeloid differentiation","volume":"142","author":"Zhang","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2026.105406_bib0040","doi-asserted-by":"crossref","first-page":"5303","DOI":"10.1158\/1078-0432.CCR-08-2941","article-title":"Complexity of CEBPA dysregulation in human acute myeloid leukemia","volume":"15","author":"Pabst","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.exphem.2026.105406_bib0041","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102643","article-title":"RNA activation of CEBPA improves leukemia treatment","volume":"36","author":"Kovecses","year":"2025","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.exphem.2026.105406_bib0042","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.stemcr.2019.10.007","article-title":"Effective and rapid generation of functional neutrophils from induced pluripotent stem cells using ETV2-modified mRNA","volume":"13","author":"Brok-Volchanskaya","year":"2019","journal-title":"Stem Cell Reports"},{"key":"10.1016\/j.exphem.2026.105406_bib0043","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s12015-018-9805-1","article-title":"Optimization of synthetic mRNA for highly efficient translation and its application in the generation of endothelial and hematopoietic cells from human and primate pluripotent stem cells","volume":"14","author":"Suknuntha","year":"2018","journal-title":"Stem Cell Rev Rep"},{"key":"10.1016\/j.exphem.2026.105406_bib0044","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41392-022-01007-w","article-title":"mRNA-based therapeutics: powerful and versatile tools to combat diseases","volume":"7","author":"Qin","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.exphem.2026.105406_bib0045","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3390\/vaccines12020165","article-title":"Dendritic cells as a therapeutic strategy in acute myeloid leukemia: vaccines","volume":"12","author":"Palomares","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.exphem.2026.105406_bib0046","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/j.ymthe.2025.03.052","article-title":"CAR-T cell therapy for treatment of acute myeloid leukemia, advances and outcomes","volume":"33","author":"Khalifeh","year":"2025","journal-title":"Mol Ther"},{"key":"10.1016\/j.exphem.2026.105406_bib0047","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2026.105406_bib0048","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s12943-023-01889-6","article-title":"Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: immune escape mechanisms and current implications for therapy","volume":"22","author":"Sauerer","year":"2023","journal-title":"Mol Cancer"},{"key":"10.1016\/j.exphem.2026.105406_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116132","article-title":"Immunotherapies of acute myeloid leukemia: Rationale, clinical evidence and perspective","volume":"171","author":"Wu","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.exphem.2026.105406_bib0050","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1038\/s41375-024-02217-7","article-title":"Targeting the innate immune system in pediatric and adult AML","volume":"38","author":"Perzolli","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2026.105406_bib0051","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.117858","article-title":"Revolutionizing cancer treatment: the power of dendritic cell-based vaccines in immunotherapy","volume":"184","author":"Sheykhhasan","year":"2025","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.exphem.2026.105406_bib0052","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1002\/cncr.30696","article-title":"Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemia","volume":"123","author":"Khoury","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.exphem.2026.105406_bib0053","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood-2017-04-780155","article-title":"Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia","volume":"130","author":"Anguille","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2026.105406_bib0054","doi-asserted-by":"crossref","first-page":"e1117","DOI":"10.1002\/cti2.1117","article-title":"Toll-like receptor 7\/8-matured RNA-transduced dendritic cells as post-remission therapy in acute myeloid leukaemia: results of a phase I trial","volume":"9","author":"Lichtenegger","year":"2020","journal-title":"Clin Transl Immunology"},{"key":"10.1016\/j.exphem.2026.105406_bib0055","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1038\/s41375-023-01980-3","article-title":"WT1 and PRAME RNA-loaded dendritic cell vaccine as maintenance therapy in de novo AML after intensive induction chemotherapy","volume":"37","author":"Fl\u00f8isand","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2026.105406_bib0056","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2026.105406_bib0057","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell Lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2026.105406_bib0058","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood.2024024063","article-title":"Honing CAR T cells to tackle acute myeloid leukemia","volume":"145","author":"Haubner","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2026.105406_bib0059","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.omto.2023.07.003","article-title":"Anti-CD117 CAR T cells incorporating a safety switch eradicate human acute myeloid leukemia and hematopoietic stem cells","volume":"30","author":"Magnani","year":"2023","journal-title":"Mol Ther Oncolytics"},{"key":"10.1016\/j.exphem.2026.105406_bib0060","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/leu.2016.35","article-title":"High-affinity FRbeta-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity","volume":"30","author":"Lynn","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2026.105406_bib0061","doi-asserted-by":"crossref","first-page":"965","DOI":"10.3390\/ijms26030965","article-title":"Optimal chimeric antigen receptor (CAR)-mRNA for transient CAR T cell generation","volume":"26","author":"Kitte","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.exphem.2026.105406_bib65","doi-asserted-by":"crossref","first-page":"13824","DOI":"10.1073\/pnas.1008051107","article-title":"Induction of complete and molecular remissions in acute myeloid leukemia by Wilms\u2019 tumor 1 antigen-targeted dendritic cell vaccination","volume":"107","author":"Van Tendeloo","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.exphem.2026.105406_bib66","first-page":"1359","article-title":"Treating Relapsed \/ Refractory (RR) AML with biodegradable Anti-CD123 CAR modified T cells","volume":"130","author":"Cummins","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2026.105406_bib0062","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1182\/blood-2016-10-696039","article-title":"Therapeutic targeting of acute myeloid leukemia stem cells","volume":"129","author":"Pollyea","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2026.105406_bib0063","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_438662","article-title":"Advancements and challenges in the treatment of AML","volume":"44","author":"Abaza","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.exphem.2026.105406_bib0064","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1680071","article-title":"Incorporating mRNA therapeutics into biological treatments of hematologic malignancies","volume":"16","author":"Hunia","year":"2025","journal-title":"Front Immunol"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X26000391?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X26000391?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T16:44:27Z","timestamp":1779554667000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X26000391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":66,"alternative-id":["S0301472X26000391"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2026.105406","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current landscape of mRNA therapeutics for acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2026.105406","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Society for Experimental Hematology.","name":"copyright","label":"Copyright"}],"article-number":"105406"}}